A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid) With Rituximab in Subjects With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid) With Rituximab in Subjects With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2013 New trial record
    • 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top